Curis Inc. Advances Lymphoma Treatment with Emavusertib Study

Curis Inc. ((CRIS)) announced an update on their ongoing clinical study.

Curis Inc. is conducting an open-label study titled ‘CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL).’ The study aims to evaluate the safety, pharmacokinetics, and anti-cancer activity of emavusertib, alone or in combination with ibrutinib, in patients with relapsed or refractory hematologic malignancies. This research is significant as it explores potential new treatments for challenging lymphoma cases.

The study tests emavusertib, an experimental drug, both as a monotherapy and in combination with ibrutinib, a known treatment. Emavusertib is administered orally to assess its effectiveness in treating relapsed or refractory primary central nervous system lymphoma.

This interventional study is non-randomized with a sequential intervention model. It involves multiple parts to determine the optimal dosing and efficacy of the treatments. The primary purpose is treatment, with no masking involved, allowing for direct observation of the drug’s effects.

The study began on October 17, 2017, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on June 2, 2025, indicating ongoing progress and adjustments as necessary.

Curis Inc.’s study could influence its stock performance positively if results show promise, potentially attracting investor interest. The study’s progress may also impact the competitive landscape in the oncology sector, particularly among companies focusing on lymphoma treatments.

The study is currently recruiting, and further details are available on the ClinicalTrials portal.